- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01435421
Breath Test for Patients With Acute Liver Disease for Early Detection of the Need for Transplant or Recovery
Acute liver failure (ALF) results from an abrupt loss of hepatic metabolic and synthetic function and leads to encephalopathy and potentially multi-organ dysfunction. Aetiologies include autoimmune and metabolic diseases, infectious agents and hepatotoxins. Worldwide, infectious hepatitis (A, B and E) is the most common cause. In Western Europe and the USA, ALF is most frequently caused by paracetamol intoxication.
The MBT can produce immediate results to aid in decision making in patients with acute liver disease. Such a test may affect decision-making regarding transplantation in this setting, facilitate appropriate discharge from critical care to other hospital units and to home, provide point of care assessment of therapeutic interventions.
The BreathID can potentially help in determining:
- Parameter to include patients in transplant list (the UNOS 1A group)
- Identification that patient deteriorates and needs extended hospitalization/referral to ICU/change in management
- An addition to the MELD and or other scores to estimate risk in other acute patients
- Additional information to that of other commonly utilized prognostic scoring systems
The primary end-point of the study is to develop a model to predict deterioration of the liver disease, which incorporates measurements from the MBT along with other potential variables. The data collected will be used to develop a prediction model using data-mining methodology (linear and non-linear regression models, binary trees, neural networks, etc…). The predictive models may include measurements from the MBT, blood test results, as single measurements or as trend over time. The model that will be developed, will attempt to predict the disease deterioration vs. recovery accurately, at an earlier time point than the standard procedure. A threshold will then be determinate based on adequate sensitivity and specificity levels.
Study Overview
Status
Conditions
Study Type
Enrollment (Anticipated)
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Adult men or women (>18 years of age).
- Acute Liver insult
- No evidence of cirrhosis (unless clinical acute Wilsons)
- INR > 1.5
- Duration of illness < 24 weeks -
Exclusion Criteria:
- Patient with any chronic liver disease
- Patient has severe congestive heart failure
- Patient has severe pulmonary hypertension
- Patient has chronic renal insufficiency with severe cardiac disease
- Patient has previous surgical bypass surgery for morbid obesity
- Patient has extensive small bowel resection
- Patient with established extra-hepatic auto-immune disease on long term treatment
- Patient is a recipient of any organ transplant (within the last 3 months)- Patient with proven or suspected hepatocellular carcinoma
- Patient is pregnant
- Patient allergic to paracetamol (such as Tylenol or any other related medications)
- Patients in whom oral intake is contra-indicated
- Patient, based on the opinion of the investigator, should not be enrolled into this study
- Patients or their nominated representative is unwilling to sign informed consent
- Patients that are participating in other clinical trials evaluating experimental treatments or procedures, not including observatory trials -
Study Plan
How is the study designed?
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- ALF-BID-1108-HMO-CTIL
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Acute Liver Failure
-
HLB Cell Co., Ltd.UnknownAcute-On-Chronic Liver Failure | Acute Liver FailureKorea, Republic of
-
Third Affiliated Hospital, Sun Yat-Sen UniversityWithdrawnAcute-On-Chronic Liver Failure | Acute Liver FailureChina
-
Institute of Liver and Biliary Sciences, IndiaCompletedAcute Liver FailureIndia
-
Beijing Continent Pharmaceutical Co, Ltd.RecruitingAcute-On-Chronic Liver Failure | Acute Liver FailureChina
-
Institute of Liver and Biliary Sciences, IndiaCompletedAcute Liver Failure | Acute on Chronic Liver FailureIndia
-
Chulalongkorn UniversityRecruitingAcute-On-Chronic Liver Failure | Acute on Chronic Hepatic FailureThailand
-
Tianjin Weikai Bioeng., Ltd.Tianjin Nankai HospitalUnknownLiver Failure, Acute on ChronicChina
-
University of EdinburghNHS LothianNot yet recruitingAcute on Chronic Hepatic Failure | Acute Liver Failure | Acute Liver Injury
-
Nanfang Hospital of Southern Medical UniversityCompletedLiver Injury | Liver Failure, Acute on Chronic
-
Third Affiliated Hospital, Sun Yat-Sen UniversityWithdrawnLiver Failure, Acute on ChronicChina